CORONA REMEDIES LIMITED

Scale -

Revenue is 1403 Rs Cr; Annual Growth is 17 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 17 %
Ebitda is 304 Rs Cr; Annual Growth is 24 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 31 %
PBT is 80.35 Rs Cr; Annual Growth is 21 %; in Top Quartile; 5 Year CAGR is 30 %
PAT is 185 Rs Cr; Annual Growth is 24 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 30 %
Quarterly Revenue is 422 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile

PBDIT Margin is 21.67 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 12 %
PAT Margin is 13.19 %; Continuous Growth over 3 years; 5 Year CAGR is 11 %
Quarterly Profit margin is 14 %; Continuous Growth over 3 Quarters
Quarterly Ebitda Margin is 22 %; in Top Quartile

Inventory Turnover Ratio is 11.03; Continuous Growth over 3 years; in Top Quartile
Operating cash flow is 229 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 31 %

Current Ratio is 0.96; Annual Decline is -32 %; in Bottom Quartile; 5 Year CAGR is -23 %
Quick Ratio is 0.62; in Bottom Quartile; 5 Year CAGR is -23 %

Long term Debt is 0 Rs Cr; Annual Decline is -100 %; Continuous Decline over 3 years

Debt/Equity is 0.19; Annual Growth is 90 %; 5 Year CAGR is 167 %
Total Debt is 143 Rs Cr; Annual Growth is 128 %; in Top Quartile; 5 Year CAGR is 294 %
Contingent Liabilities is 43.6 Rs Cr; in Top Quartile

Operating cashflow/PAT is 124 %; in Top Quartile; Continuous Decline over 3 years
Exceptional Items/PBT is -8 %; in Bottom Quartile

Sector

Major Subsidiaries/Associates

Key Clients

Products

Product details

Capacity/ Production

Key Facilities

Key Certifications

Raw materials

Search: